Suchergebnisse - "Vierling, John M"

PubPharm (266)

1

Consensus Guidelines : Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy

enthalten in: Drug safety | 2024

von Cohen, E. | Regev, A. | Garg, A. | +10

2

Autoimmune hepatitis : Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data

enthalten in: Vaccine | 2024

von Kochhar, S. | Assis, D. | Mack, C. | +7

3

The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis : Close is not good enough!

enthalten in: Hepatology (Baltimore, Md.) | 2024

von Cholankeril, G. | Vierling, J.

4

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

enthalten in: The New England journal of medicine | 2024

von Kowdley, K. | Bowlus, C. | Levy, C. | +102

5

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

enthalten in: The New England journal of medicine | 2024

von Hirschfield, G. | Bowlus, C. | Mayo, M. | +94

6

Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy

enthalten in: Drug safety | 2024

von Cohen, E. | Regev, A. | Garg, A. | +10

7

Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis : Themes and Concepts

enthalten in: Gastroenterology | 2024

von Trivedi, P. | Hirschfield, G. | Adams, D. | +1

8

Open-label, clinical trial extension : Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

enthalten in: Alimentary pharmacology & therapeutics | 2024

von Mayo, M. | Vierling, J. | Bowlus, C. | +20

9

Editorial : The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply

enthalten in: Alimentary pharmacology & therapeutics | 2024

von Mayo, M. | Vierling, J. | Bowlus, C.

10

Open‐label, clinical trial extension : Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

enthalten in: Alimentary Pharmacology & Therapeutics | 2024

von Mayo, M. | Vierling, J. | Bowlus, C. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[27]